<DOC>
	<DOCNO>NCT01355146</DOCNO>
	<brief_summary>The purpose study proof increase patient satisfaction preservation quality life patient Morbus Fabry disease receive Enzyme Replacement Therapy Replagal ( Agalsidase alfa ) home compare receive infusion clinic doctor 's practice .</brief_summary>
	<brief_title>Home Therapy With Replagal Fabry Disease</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>INCLUSION CRITERIA : Male female patient confirm diagnosis Fabry disease Age &gt; 4 year Patient Replagal since least 12 week 速 therapy The patient compliant , previous Replagal 速 infusion perform approximately every 2 week center close home hospital / general practitioner Patient well tolerate Replagal 速 therapy , last 12 week inclusion study significant infusion reaction The patient select inclusion study home infusion therapy consent ( legal representative ) The patient / lawful . Representative consent write participate study . Patient/legal representative give consent participation study Patient/legal representative decline Replagal速 home therapy The patient participate clinical trial medicinal product</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Patients prove Fabry 's Disease</keyword>
</DOC>